218 related articles for article (PubMed ID: 23141780)
1. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
[TBL] [Abstract][Full Text] [Related]
2. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
[TBL] [Abstract][Full Text] [Related]
4. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
6. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS
J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876
[TBL] [Abstract][Full Text] [Related]
9. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in patients with advanced renal cell carcinoma.
Muriel López C; Esteban E; Berros JP; Pardo P; Astudillo A; Izquierdo M; Crespo G; Sanmamed M; Fonseca PJ; Martínez-Camblor P
Clin Genitourin Cancer; 2012 Dec; 10(4):262-70. PubMed ID: 22959659
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract][Full Text] [Related]
12. Carbonic anhydrase IX is expressed in mesothelioma and metastatic clear cell renal cell carcinoma of the lung.
Ramsey ML; Yuh BJ; Johnson MT; Yeldandi AV; Zynger DL
Virchows Arch; 2012 Jan; 460(1):89-93. PubMed ID: 22143934
[TBL] [Abstract][Full Text] [Related]
13. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials.
Zhou GX; Ireland J; Rayman P; Finke J; Zhou M
Urology; 2010 Feb; 75(2):257-61. PubMed ID: 19963243
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of cytochrome P4A11 (CYP4A11), carbonic anhydrase 9 (CAIX) and Ki67 in renal cell carcinoma; diagnostic relevance and relations to clinicopathological parameters.
Elfakharany HK; Ghoraba HM; Gaweesh KA; Eldeen AAS; Eid AM
Pathol Res Pract; 2024 Jan; 253():155070. PubMed ID: 38183818
[TBL] [Abstract][Full Text] [Related]
15. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
[TBL] [Abstract][Full Text] [Related]
16. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.
Zerati M; Leite KR; Pontes-Junior J; Segre CC; Reis ST; Srougi M; Dall'Oglio MF
Int Braz J Urol; 2013; 39(4):484-92. PubMed ID: 24054396
[TBL] [Abstract][Full Text] [Related]
17. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Oosterwijk-Wakka JC; Kats-Ugurlu G; Leenders WP; Kiemeney LA; Old LJ; Mulders PF; Oosterwijk E
BJU Int; 2011 Jan; 107(1):118-25. PubMed ID: 20346054
[TBL] [Abstract][Full Text] [Related]
18. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
[TBL] [Abstract][Full Text] [Related]
19. [Value of MN/CAIX in the diagnosis of renal cell carcinoma].
Jiang YD; Ren F; Zheng SB
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):412-4. PubMed ID: 22445996
[TBL] [Abstract][Full Text] [Related]
20. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Ferté C; Koscielny S; Albiges L; Rocher L; Soria JC; Iacovelli R; Loriot Y; Fizazi K; Escudier B
Eur Urol; 2014 Apr; 65(4):713-20. PubMed ID: 23993162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]